Currently, the most relevant immune checkpoints in the field of cancer immunotherapy are Cytotoxic T-Lymphocyte Associated protein 4 (CTLA-4) and Programmed cell Death protein 1 (PD1), which are expressed on the surface of T lymphocytes. This evidence concerns the gene CTLA4 and cancer.